

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Encorafenib in combination with binimetinib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma ID923

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Array BioPharma and Pierre Fabre (encorafenib with binimetinib) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Black Health Agency • British Skin Foundation • Cancer 52 • Cancer Black Care • Cancer Equality • HAWC • Helen Rollason Cancer Charity • Independent Cancer Patients' Voice • Macmillan Cancer Support • Maggie's Centres • Marie Curie Cancer Care • Melanoma UK • Muslim Council of Britain • OcuMel UK • Skcin - Karen Clifford Skin Cancer Charity • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • British Association of Dermatologists • British Association of Skin Cancer Specialist Nurses • British Dermatological Nursing Group • British Geriatrics Society • British Institute of Radiology • British Psychosocial Oncology Society • Cancer Research UK • Melanoma Focus • Primary Care Dermatology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • All Wales Therapeutics and Toxicology Centre • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • Novartis (dabrafenib, trametinib) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Society for Dermatological Surgery • Cochrane Skin Group • Institute of Cancer Research • MRC Clinical Trials Unit • Myfanwy Townsend Melanoma Research Fund • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research • Skin Cancer Research Fund • Skin Treatment & Research Trust

Provisional matrix for the technology appraisal of encorafenib in combination with binimetinib for treating advanced (unresectable or metastatic) BRAF V600 mutation-positive melanoma ID923

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association • UK Health Forum • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS Harrow CCG • NHS Birmingham CrossCity CCG • NHS England • Welsh Government 	<p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not.

Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.